First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis

[1] Canino C(2019)Targeting angiogenesis in metastatic renal cell carcinoma Expert Rev Anticancer Ther 19 245-257

[2] Perrone L(2003)The von hippel-lindau protein, vascular endothelial growth factor, and kidney cancer N Engl J Med 349 419-421

[3] Bosco E(2021)Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 32 422-423

[4] Saltalamacchia G(2019)Tumor microenvironment dynamics in clear-cell renal cell carcinoma Cancer Discov 9 1349-1357

[5] Mosca A(2018)Targeting VEGF/VEGFR to modulate antitumor immunity Front Immunol 9 978-275

[6] Rizzo M(2020)A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy Cancer Drug Resist 3 252-127

[7] George DJ(2021)Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials Eur J Cancer 154 120-68

[8] Kaelin WG(2022)Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma Target Oncol 17 61-712

[9] Powles T(2022)Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial Nat Med 28 704-625

[10] Vuong L(2022)Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis Immunotherapy 14 617-754

[1] Canino C(2019)Targeting angiogenesis in metastatic renal cell carcinoma Expert Rev Anticancer Ther 19 245-257

[2] Perrone L(2003)The von hippel-lindau protein, vascular endothelial growth factor, and kidney cancer N Engl J Med 349 419-421

[3] Bosco E(2021)Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 32 422-423

[4] Saltalamacchia G(2019)Tumor microenvironment dynamics in clear-cell renal cell carcinoma Cancer Discov 9 1349-1357

[5] Mosca A(2018)Targeting VEGF/VEGFR to modulate antitumor immunity Front Immunol 9 978-275

[6] Rizzo M(2020)A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy Cancer Drug Resist 3 252-127

[7] George DJ(2021)Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials Eur J Cancer 154 120-68

[8] Kaelin WG(2022)Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma Target Oncol 17 61-712

[9] Powles T(2022)Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial Nat Med 28 704-625

[10] Vuong L(2022)Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis Immunotherapy 14 617-754